Company profile for MC2 Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

MC2 Therapeutics is a privately held pharmaceutical company committed to introduce a new standard of topical therapies for chronic inflammatory conditions designed for fast relief of symptoms and convenience in daily routines thereby responding to patients’ requests. Our proprietary PAD™ Technology allows us to go beyond technical limitations of conventional aqueous formulations such as creams and lotions and develop a new...
MC2 Therapeutics is a privately held pharmaceutical company committed to introduce a new standard of topical therapies for chronic inflammatory conditions designed for fast relief of symptoms and convenience in daily routines thereby responding to patients’ requests. Our proprietary PAD™ Technology allows us to go beyond technical limitations of conventional aqueous formulations such as creams and lotions and develop a new standard of innovative PAD™ Creams and PAD™ Eye Drops that are truly designed to become life companions for people with chronic inflammatory skin or eye conditions.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Denmark
Address
Address
Agern Allé 24-26 DK-2970 Hoersholm
Telephone
Telephone
+45 2018 1111
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.contractpharma.com/breaking-news/mc2-therapeutics-appoints-trine-ahlgreen-ceo/

CONTRACTPHARMA
27 May 2025

https://www.globenewswire.com/news-release/2024/05/13/2880089/0/en/MC2-Therapeutics-Receives-Positive-Feedback-from-FDA-pre-IND-Meeting-and-Updates-on-Indication-Expansion-Strategy.html

GLOBENEWSWIRE
13 May 2024

https://www.prnewswire.com/news-releases/hyphens-pharma-licenses-wynzora-cream-for-asean-countries-from-mc2-therapeutics-302086586.html

PR NEWSWIRE
12 Mar 2024

https://www.globenewswire.com//news-release/2024/02/26/2834992/0/en/MC2-Therapeutics-to-Present-at-Upcoming-Conferences.html

GLOBENEWSWIRE
26 Feb 2024

https://www.globenewswire.com//news-release/2023/12/07/2792387/0/en/MC2-Therapeutics-Announces-Completion-of-Enrollment-in-MC2-25-Ph2-Chronic-Kidney-Disease-associated-Pruritus-Trial.html

GLOBENEWSWIRE
07 Dec 2023

https://www.globenewswire.com//news-release/2023/11/23/2785220/0/en/MC2-Therapeutics-Announces-First-Patients-Enrolled-in-Phase-2-Proof-of-Concept-Clinical-Trial-in-Vulvar-Lichen-Sclerosus.html

GLOBENEWSWIRE
23 Nov 2023

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty